The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
Open accessAbstract
Introduction: B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of rituximab (RTX) treated RA patients have a poor response. We investigated whether baseline gene expression levels can discriminate between clinical non-responders and responders to RTX. Methods: In 14 consecutive RA patients starting on RTX (test cohort), gene expression profiling on whole peripheral blood RNA was performed by Illumina ® HumanHT beadchip microarrays. Supervised cluster analysis was used to identify genes expressed differentially at baseline between responders and non-responders based on both a difference in 28 joints disease activity score (ΔDAS28 < 1.2) and European League against Rheumatism (EULAR) response criteria after six months RTX. Genes of interest were measured by quantitative real-time PCR and tested for their predictive value using receiver operating characteristics (ROC) curves in an independent validation cohort ( n = 26). Results: Genome-wide microarray analysis revealed a marked variation in the peripheral blood cells between RA patients before the start of RTX treatment. Here, we demonstrated that only a cluster consisting of interferon (IFN) type I network genes, represented by a set of IFN type I response genes (IRGs), that is, LY6E, HERC5, IFI44L, ISG15, MxA, MxB, EPSTI1 and RSAD2 , was associated with ΔDAS28 and EULAR response outcome ( P = 0.0074 and P = 0.0599, respectively). Based on the eight IRGs an IFN-score was calculated that reached an area under the curve (AUC) of 0.82 to separate non-responders from responders in an independent validation cohort of 26 patients using Receiver Operator Characteristics (ROC) curves analysis according to ΔDAS28 < 1.2 criteria. Advanced classifier analysis yielded a three IRG-set that reached an AUC of 87%. Comparable findings applied to EULAR non-response criteria. Conclusions: This study demonstrates clinical utility for the use of baseline IRG expression levels as a predictive biomarker for non-response to RTX in RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Lewis, M. J., Barnes, M. R., Blighe, K., Goldmann, K., Rana, S., Hackney, J. A., Ramamoorthi, N., John, C. R., Watson, D. S., Kummerfeld, S. K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.091 · Cited by 422
Type I interferon in rheumatic diseases
Muskardin, T. L. W., & Niewold, T. B. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.31 · Cited by 308
Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01789-0 · Cited by 294
Woetzel, D., Huber, R., Kupfer, P., Pohlers, D., Pfaff, M., Driesch, D., Häupl, T., Koczan, D., Stiehl, P., Guthke, R., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4526 · Cited by 276
Metadata
- Authors
- Raterman, H. G., Vosslamber, S., de Ridder, S., Nurmohamed, M. T., Lems, W. F., Boers, M., van de Wiel, M., Dijkmans, B. A., Verweij, C. L., & Voskuyl, A. E.
- Venue
- Arthritis Research & Therapy
- Published
- 2012-04-27
- Volume
- 14
- Issue
- 2
- Pages
- R95-R95
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2122295644
- Cited by
- 180
- References
- 1
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. https://app.cochat.ai/papers/10.1186/ar3819
- The paper
- Raterman, H. G., Vosslamber, S., de Ridder, S., Nurmohamed, M. T., Lems, W. F., Boers, M., van de Wiel, M., Dijkmans, B. A., Verweij, C. L., & Voskuyl, A. E. (2012). The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Research & Therapy. https://doi.org/10.1186/ar3819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.